Novo Nordisk Set to Report Q2 Results With $11.27 Billion Revenue, 82-Cent EPS Expected
Updated
Updated · Yahoo Finance · Aug 3
Novo Nordisk Set to Report Q2 Results With $11.27 Billion Revenue, 82-Cent EPS Expected
1 articles · Updated · Yahoo Finance · Aug 3
Summary
Aug. 5 is the key date for Novo Nordisk’s second-quarter report, with analysts projecting $11.27 billion in revenue and earnings of 82 cents a share.
Semaglutide drugs are expected to drive the quarter, as investors focus on sales of diabetes treatment Ozempic and obesity drug Wegovy.
Oral Wegovy could add momentum after its U.S. launch in January; the pill has already topped 3 million prescriptions and won EU approval earlier this month.
Estimate revisions have turned weaker ahead of the release, with 2026 EPS forecasts cut to $3.38 from $3.46 and 2027 views lowered to $3.27 from $3.44.
Novo Nordisk has still beaten earnings estimates in each of the past four quarters, averaging a 16.86% surprise, though its current Earnings ESP is 0.00% with a Zacks Rank #5.